For example, imatinib, the first BCR/ABL inhibitor, was discovered to exert an effect on the potentiation of all-trans-retinoic acid (ATRA)-induced AML differentiation [6], and the epidermal growth factor receptor inhibitor gefitinib was later confirmed to enhance the ATRA-induced differentiation of AML cells [7], [8]. Here, BCR is linked to acute myeloid leukemia.